|Bid||0.4280 x 1400|
|Ask||0.4297 x 1300|
|Day's Range||0.4101 - 0.4350|
|52 Week Range||0.2700 - 0.8300|
|Beta (3Y Monthly)||3.24|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 10, 2016 - Mar 14, 2016|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||3.30|
Protalix BioTherapeutics, Inc. (PLX) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front.
CARMIEL, Israel, Dec. 17, 2018 (GLOBE NEWSWIRE) -- Protalix BioTherapeutics, Inc. (NYSE American:PLX) (PLX.TA), a biopharmaceutical company focused on the development and commercialization of recombinant therapeutic proteins expressed through its proprietary plant cell-based expression system, ProCellEx®, today announced the completion of enrollment for the BRIDGE phase III clinical trial of pegunigalsidase alfa (PRX-102) for the treatment of Fabry disease. Additionally, the Company provided an update on the enrollment for the BALANCE and BRIGHT phase III clinical trials which, collectively with the BRIDGE study, comprise the phase III clinical development program for PRX-102 for the treatment of Fabry disease. The BRIGHT study is approximately 90% enrolled and the BALANCE study is approximately 70% enrolled.
Protalix (PLX) delivered earnings and revenue surprises of -150.00% and -91.71%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Carmiel, Israel-based company said it had a loss of 10 cents. The drug developer posted revenue of $663,000 in the period. The company's shares closed at 49 cents. A year ago, ...
CARMIEL, Israel, Nov. 07, 2018 -- Protalix BioTherapeutics, Inc. (NYSE American:PLX, TASE:PLX), a biopharmaceutical company focused on the development and commercialization of.
Protalix (PLX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CARMIEL, Israel, Oct. 29, 2018 -- Protalix BioTherapeutics, Inc. (NYSE American:PLX, TASE:PLX), a biopharmaceutical company focused on the development and commercialization of.
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Biotech stocks hitting 52-week highs on Oct. 3) Amarin Corporation plc (NASDAQ: AMRN ) BIOLINERX Ltd/S ...
Biotech shares saw further momentum last week, following up on the gains of the previous two weeks. Will the momentum continue in the upcoming week? Here are the catalytic events that could drive the sector. ...
NEW YORK, NY / ACCESSWIRE / September 24, 2018 / Shares of GTx were deep in the red on Friday on disappointing news that the company’s only drug candidate had filed a mid-stage clinical trial. Shares of Protalix BioTherapeutics on the other hand were soaring on positive preliminary data. GTx, Inc. shares closed down a little over 92% on Friday, making it one of the biggest decliners on the Nasdaq.
Protalix (PLX) delivered earnings and revenue surprises of -33.33% and -71.34%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
In this article, I will take a quick look at Protalix BioTherapeutics Inc’s (NYSEMKT:PLX) recent ownership structure – an unconventional investing subject, but an important one. The impact of aRead More...
On a per-share basis, the Carmiel, Israel-based company said it had a loss of 8 cents. The drug developer posted revenue of $2 million in the period. The company's shares closed at 50 cents. A year ago, ...
NEW YORK, NY / ACCESSWIRE / August 9, 2018 / Protalix Biotherapeutics, Inc. (NYSE: PLX ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 9, 2018 at 8:30 AM Eastern ...
LONDON, UK / ACCESSWIRE / July 31, 2018/ If you want a free Stock Review on SRPT sign up now at www.wallstequities.com/registration. Losses were broad based as seven out of nine sectors finished the trading session in red. WallStEquities.com has initiated research reports on the following Biotechnology stocks: Protalix BioTherapeutics Inc. (NYSE AMER: PLX), Radius Health Inc. (NASDAQ: RDUS), Rigel Pharmaceuticals Inc. (NASDAQ: RIGL), and Sarepta Therapeutics Inc. (NASDAQ: SRPT).